Takeda’s Ninlaro approved for NHS use via CDF
Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on the NHS, after cost regulators cleared its use through the Cancer Drugs Fund (CDF).
Read More
Tag: ixazomib
Takeda’s Ninlaro rejected by NICE for multiple myeloma
Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its mutilple myeloma drug Ninlaro following an initial rejection by the cost watchdog.
Read More
Conditional EU nod for Takeda’s Ninlaro
Takeda Pharmaceutical’s Ninlaro has been awarded conditional marketing approval in Europe as a second-line treatment for multiple myeloma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
